|
1
|
Dye C, Floyd K and Uplekar M: Global
tuberculosis control: Surveillance planning financing. WHO report
2008. World Health Organization. (Geneva). 3002008.
|
|
2
|
Yang XY, Chen QF, Li YP and Wu SM:
Mycobacterium vaccae as adjuvant therapy to
anti-tuberculosis chemotherapy in never-treated tuberculosis
patients: A meta-analysis. PLoS One. 6:e238262011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Abou-Zeid C, Gares MP, Inwald J, Janssen
R, Zhang Y, Young DB, Hetzel C, Lamb JR, Baldwin SL, Orme IM, et
al: Induction of a type 1 immune response to a recombinant antigen
from Mycobacterium tuberculosis expressed in Mycobacterium
vaccae. Infect Immun. 65:1856–1862. 1997.PubMed/NCBI
|
|
4
|
Hernandez-Pando R, Pavön L, Arriaga K,
Orozco H, Madrid-Marina V and Rook G: Pathogenesis of tuberculosis
in mice exposed to low and high doses of an environmental
mycobacterial saprophyte before infection. Infect Immun.
65:3317–3327. 1997.PubMed/NCBI
|
|
5
|
Skinner MA, Yuan S, Prestidge R, Chuk D,
Watson JD and Tan PL: Immunization with heat-killed
Mycobacterium vaccae stimulates CD8+ cytotoxic T
cells specific for macrophages infected with Mycobacterium
tuberculosis. Infect Immun. 65:4525–4530. 1997.PubMed/NCBI
|
|
6
|
Liberati A, Altman DG, Tetzlaff J, Mulrow
C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J
and Moher D: The PRISMA statement for reporting systematic reviews
and meta-analyses of studies that evaluate healthcare
interventions: Explanation and elaboration. BMJ. 339:b27002009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Higgins JP, Thompson SG, Deeks JJ and
Altman DG: Measuring inconsistency in meta-analyses. BMJ.
327:557–560. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Luo Y, Lu S and Guo S: Immunotherapeutic
effect of Mycobacterium vaccae on multi-drug resistant
pulmonary tuberculosis. Zhonghua Jie He He Hu Xi Za Zhi. 23:85–88.
2000.(In Chinese). PubMed/NCBI
|
|
9
|
Song XD, Ren YW, Zhu H, Ji Q and Xu Y: The
effect of Mycobacterium vaccae on multi-drug resistant
pulmonary tuberculosis of 36 cases. Zhongguo Zong He Lin Chuang.
18:482002.(In Chinese).
|
|
10
|
Wu C, Yu GC and Cheng CX: Effect of
Mycobacterium vaccae on multi-drug resistant pulmonary
tuberculosis of 43 cases. Zhongguo She Qu Yi Shi: Yi Xue Zhuan Ye.
6:15–16. 2004.(In Chinese).
|
|
11
|
Zheng XM, Li SH and Xing BC: Short-term
effect of treatment protocol utilizing levofloxacin, pasiniazide
and M. Vaccae on multi-drug resistant pulmonary
tuberculosis. Di Yi Jun Yi Da Xue Xue Bao. 24:574–578. 2004.(In
Chinese). PubMed/NCBI
|
|
12
|
Chen SQ, Liu JY and Weng LZ:
Pharmacoeconomics evaluation for the treatment of Mycobacterium
vaccae on multidrug-tuberculosis. Fu Jian Yi Yao Za Zhi.
27:129–131. 2005.(In Chinese).
|
|
13
|
Yao HB, Shang HZ, Guo L, Wang YL, Feng JM
and Ma JM: The observation of the effect of the treatment of
multi-drug resistant pulmonary tuberculosis with M Vaccae.
Zhongguo Fang Lao Za Zhi. 27:389–392. 2005.(In Chinese).
|
|
14
|
Liu YH: Effect of Mycobacterium
vaccae as an adjunctive therapy on multidrug resistant
tuberculosis. Zhongguo Ji Ceng Yi Yao. 13:492–493. 2006.(In
Chinese).
|
|
15
|
Wang JY and Lin DW: Effect of
Mycobacterium vaccae on multidrug resistant tuberculosis.
Hua Xia Yi Xue. 19:443–445. 2006.(In Chinese).
|
|
16
|
Lan K: Effect of Mycobacterium
vaccae as an adjunctive therapy on multidrug resistant
pulmonary tuberculosis. Nei Ke. 2:47–48. 2007.(In Chinese).
|
|
17
|
Zhao SX: Effect of Mycobacterium
vaccae vaccine in treatment of multi-drug resistant
tuberculosis. Lin Chuang Fei Ke Za Zhi. 13:927–928. 2008.(In
Chinese).
|
|
18
|
Chu NH, Luo YA, Zhu LZ, Fu Y, Ye Z, Xiao
H, Wang W, Yuan S, Zhang X, Lu S, et al: A controlled clinical
study of long course chemotherapy regimens combined with
immunopotentiator in the treatment of multi-drug resistant
pulmonary tuberculosis. Zhongguo Fang Lao Za Zhi. 31:10–14.
2009.(In Chinese).
|
|
19
|
Gu XY: Effect of Mycobacterium
vaccae as an adjunctive therapy on 70 multidrug resistant
tuberculosis cases. Lin Chuang Fei Ke Za Zhi. 14:1677–1678.
2009.(In Chinese).
|
|
20
|
Hong Y and Lin XH: Effect of
Mycobacterium vaccae vaccine plus anti-tuberculosis drugs on
multi-resistant tuberculosis. Zhongguo Re Dai Yi Xue. 9:850–851.
2009.(In Chinese).
|
|
21
|
Wang YL: Study of microcalory united with
chemotherapeutics on tuberculosis of more drugs fast. Xian Dai
Zhong Xi Yi Jie He Za Zhi. 18:2362–2363. 2009.(In Chinese).
|
|
22
|
Xi XE, Zhang HQ and Zhang LG: Frozen-dried
M. Vaccae Vavvine for therapy combined with general
chemotherapy for multi-drug resistance pulmonary tuberculosis. Xin
Xiang Yi Xue Yuan Xue Bao. 26:355–357. 2009.(In Chinese).
|
|
23
|
Liu XD: MV immune treatment of multi-drug
resistant tuberculosis 32 cases of clinical curative effect
observation. Gan Nan Yi Xue Yuan Xue Bao. 30:4122010.(In
Chinese).
|
|
24
|
Mei YZ and Yang LM: Effects of
Mycobacterium vaccae vaccine on multi-drug resistant
pulmonary tuberculosis. Zhongguo Re Dai Yi Xue. 10:693–694.
2010.(In Chinese).
|
|
25
|
Zhang JD: MV with the chemotherapy drug
therapy retreatment on case of multi-drug resistant tuberculosis
curative effect observation. Lin Chuang Fei Ke Za Zhi.
15:1489–1490. 2010.(In Chinese).
|
|
26
|
Sheng GL: Clinical analysis of
Vaccae combined anti-tuberculosis drugs in treatment of
multidrug-resistant tuberculosis. Yi Yao Lun Tan Za Zhi. 32:37–38.
2011.(In Chinese).
|
|
27
|
Wang L and Jin ZD: Effect of
Mycobacterium vaccae vaccine on multi-drug resistant
pulmonary tuberculosis. Zhongguo She Qu Yi Shi: Yi Xue Zhuan Ye.
13:522011.(In Chinese).
|
|
28
|
Yang SY: Clinical analysis of
Vaccae combined anti-tuberculosis drugs in treatment of 60
cases of multidrug-resistant tuberculosis. Zhongguo Yi Yao Zhi Nan.
9:105–106. 2011.(In Chinese).
|
|
29
|
Zhou Y: Clinical observation of
mycobacterium bovis combination with chemotherapy on
multidrug-resistant mycobacterium. Chong Qin Yi Xue. 40:341–342.
2011.(In Chinese).
|
|
30
|
Chen YJ: Chemical joint MV clinical
research for the treatment of senile multi-drug resistant
tuberculosis. Zhong Wai Yi Xue Yan Jiu. 10:442012.(In Chinese).
|
|
31
|
Yin LS, Zhu M and Zhou M: Clinical
observation on buqin tablet combined with Western medicine for 17
cases of multidrug-resistant tuberculosis. Zhong Yi Za Zhi.
53:669–672. 2012.(In Chinese).
|
|
32
|
Zhang XL and Huang D: Effects of cellular
immunity improvement on chemotherapy efficacy and prognosis of
patients with multidrug-resistant tuberculosis. Shi Yong Yi Xue Za
Zhi. 29:1964–1966. 2013.(In Chinese).
|
|
33
|
Skrahina A, Hurevich H, Zalutskaya A,
Sahalchyk E, Astrauko A, van Gemert W, Hoffner S, Rusovich V and
Zignol M: Alarming levels of drug-resistant tuberculosis in
Belarus: Results of a survey in Minsk. Eur Respir J. 39:1425–1431.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zignol M, van Gemert W, Falzon D,
Sismanidis C, Glaziou P, Floyd K and Raviglione M: Surveillance of
anti-tuberculosis drug resistance in the world: An updated
analysis, 2007–2010. Bull World Health Organ. 90:111–119D. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Stanford JL, Bahr GM, Rook GA, Shaaban MA,
Chugh TD, Gabriel M, al-Shimali B, Siddiqui Z, Ghardani F, Shahin
A, et al: Immunotherapy with Mycobacterium vaccae as an
adjunct to chemotherapy in the treatment of pulmonary tuberculosis.
Tubercle. 71:87–93. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
World Health Organization (WHO):
Tuberculosis research and development: Report of a WHO meeting.
WHO, Geneva: 1991.
|
|
37
|
Stanford JL, Stanford CA, Grange JM, Lan
NN and Etemadi A: Does immunotherapy with heat-killed
Mycobacterium vaccae offer hope for the treatment of
multi-drug-resistant pulmonary tuberculosis? Respir Med.
95:444–447. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Schulz KF, Chalmers I, Hayes RJ and Altman
DG: Empirical evidence of bias. Dimensions of methodological
quality associated with estimates of treatment effects in
controlled trials. JAMA. 273:408–412. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Moher D, Pham B, Jones A, Cook DJ, Jadad
AR, Moher M, Tugwell P and Klassen TP: Does quality of reports of
randomised trials affect estimates of intervention efficacy
reported in meta-analyses? Lancet. 352:609–613. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jüni P, Altman DG and Egger M: Systematic
reviews in health care: Assessing the quality of controlled
clinical trials. BMJ. 323:42–46. 2001. View Article : Google Scholar : PubMed/NCBI
|
